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                                              Abstract  
 
Neurodegenerative diseases are multifactorial in nature, and taking the complex nature of these 
disorders into consideration, multi-target directed ligands may present as better options to treat 
these disorders than the classic ‘one molecule, one target’ approach. 
Neurotransmitter amines are catabolized by monoamine oxidase A and B (MAO-A and MAO-B), 
therefore they have been targeted for the treatment of neuropsychiatric and neurodegenerative 
diseases.  Besides offering a potential antidepressant action in PD, MAO-A inhibitors may also 
provide a symptomatic benefit by reducing MAO-A-catalysed oxidation of dopamine. The 
oxidative deamination reaction catalyzed by MAO-B is one of the major catabolic pathways of 
dopamine in the brain. Inhibition of this enzyme leads to enhanced dopaminergic 
neurotransmission and are currently used in the symptomatic treatment of PD. Furthermore, 
MAO-B inhibitors may also exert neuroprotective effects by reducing the concentration of 
potentially hazardous by-products produced by MAO-B-catalysed dopamine oxidation. Apoptosis 
or programmed cell death occurs in a number of neurodegenerative disorders and it has been 
proven that inhibition of the executing enzyme, caspases-3, slows down or even stops apoptosis. 
Having this in mind we focused on the propargylamine function of selegiline and the fluorophenyl 
function of safinamide, because of their inherent monoamine oxidase inhibitory activities; and 
isatin as a non-peptide inhibitor of caspase-3. Therefore we attempted to design and synthesize 
multifunctional hybrid molecules acting simultaneously to halt the apoptotic neuronal breakdown 
process and eliminate the signs and symptoms of diseases such as PD. 
Seven novel compounds were successfully synthesized utilizing multistep processes. The 
synthesis of 5-chlorosulfonyl isatin was accomplished starting from the commercially available 
isatin in two steps, which were, sulfonation using tetramethylene sulfone and chlorination with 
POCl3. Next 5-chlorosulfonyl isatin was conjugated to the fluorophenylamine derivative with the 
fluoro-function at either the ortho, meta or para position through a nucleophilic substitution 
reaction on the chlorosulfonyl position. The resultant compounds were coupled on the N position 
of the isatin function with propargyl bromide, using a microwave synthesis procedure, in a 
nucleophilic substitution reaction. The structures and purity were confirmed by nuclear magnetic 
resonance (NMR) and mass spectrometry (MS). 
In the biological evaluations recombinant human MAO-A, MAO-B and caspase 3 enzymatic 
assays were performed to determine the activity of the novel compounds at an enzymatic level. 
The inhibition percentages for these compounds were calculated and plotted against the logarithm 
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of the inhibitor concentrations to obtain a sigmoidal dose-response curve and consequently the 
IC50 value.  
The synthesized compounds showed inhibition of the MAO-A, MAO-B and caspase-3 enzymes 
at low to high micro molar concentrations. The role of the fluorophenylamine moiety in the 
synthesized compounds was significant for their multifunctional activity as shown by compounds 
3 and 4 having good inhibitory activity towards MAO-A, MAO-B and also excellent inhibitory 
activity against caspase 3, making them ideal candidates for further lead compound development 
and multifunctional drug design. The introduction of the propargylamine moiety only increased 
the MAO-A inhibitory activity; this was shown by compounds 7, 8 and 9 which exhibit good MAO-
A selectivity with low MAO-B and caspase-3 inhibitory activities. 
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                                              Chapter 1 
                                  Introduction 
 
1.1 BACKGROUND 
It has been discovered that neurodegeneration occurs in which neurons in the central nervous 
system (CNS) and the brain in particular are destroyed by several mechanisms (Araki et al. 
2001). These neurodegenerative disorders are progressive and irreversible, and a loss of 
neurons from specific regions of the brain is characteristic of these disorders (Alexi et al. 2000). 
The quality of life of patients that suffer from Huntington’s disease (HD), Alzheimer’s disease 
(AD) and Parkinson’s disease (PD) are significantly diminished, especially among the global 
aging population and it is a huge problem worldwide (Rang 2007). A vast amount of time and 
research has gone into this area of identifying what the causes are for these disorders. The 
current drugs that are available are used more for the management of these disorders rather 
than for treatment of these diseases. These disorders have a profound impact on the life of the 
affected patients and their families. Therefore there is a very strong motivation to search for the 
best treatment possible (Tarrants et al. 2010).  
Currently there are nearly 36 million people in the world that suffer from dementia and the 
numbers of people living with this disease worldwide is expected to double every 20 years. The 
estimated total cost of dementia worldwide is $604 billion dollars. A report done by the World 
Health Organization in 2012, called on all countries to recognize that dementia would be a global 
health challenge and include dementia in public health planning. (Alzheimer’s Society UK 2014). 
PD is the second most common neurodegenerative disorder after AD and affects nearly 0.3% of 
the general population (de Lau, Breteler 2006). In the United States, medication costs for an 
individual person with PD is estimated to be nearly $2,500 dollars a year, and therapeutic surgery 
can cost up to $100,000 per patient (Parkinson's Disease Foundation 2016).  
Not a single cause or process leads to a neurodegenerative disorder; instead it is the result of 
several factors which most likely include a variety of mechanistic pathways (Dauer, Przedborski 
2003). It is postulated that genetic, environmental and endogenous factors play an important part 
in neurodegenerative disorders such as AD and PD and a number of general pathways have 
been discovered that may be among the factors which are involved in different pathogenic 
cascades. These include excitotoxicity, oxidative stress and free radical formation, protein 
misfolding and aggregation, phosphorylation impairment, metal dyshomeostasis and 
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mitochondrial dysfunction. Some of these seem to happen simultaneously, resulting in the death 
of essential neuronal cells (Jellinger 2003a).  
Apoptosis or programmed type I cell death is a complicated constant mechanism to dispose of 
surplus, potentially dangerous and damaged cells resulting in apoptotic bodies which get cleared 
without activation of the immune system (Hengartner 2000). Apoptosis as seen in physiological 
cellular processes such as control of size and shape of tissue, fetal development, maintenance 
of the immune system, and cell homeostasis, all play a key role. In the case of dysregulation, 
apoptosis plays a vital role in a variety of diseases such as neurodegenerative and developmental 
deficiencies, cardiovascular and autoimmune diseases, cancer and atherosclerosis 
(Limpachayaporn et al. 2013b). Apoptotic cell death is generally characterized by several 
subcellular alterations winding up in a specific cell death program (Martins, Earnshaw 1997). The 
programmed type I cell death has been identified by three stages which are initiation, effector and 
degradation (Kroemer et al. 1995), in PD the apoptotic process most probably appears as an end-
stage process (Anglade et al. 1997). In the case of PD, upregulation of the antiapoptotic protein 
Bcl-2 (Marshall et al. 1997) and augmented levels of the proapoptotic protein Bax (Hartmann et 
al. 2001) have been seen in the substantia nigra of the affected patients. In addition, caspase 3 
and caspase 8 may act as effectors of apoptotic cell death in the brain of PD patients (Mogi et al. 
2000, Hartmann et al. 2001).  
 
1.2 ENZYME INHIBITION 
Neurotransmitter amines are catabolized by MAO-A and -B, these enzymes have been targeted 
for the treatment of neuropsychiatric and neurodegenerative diseases (Youdim, Edmondson & 
Tipton 2006a, Youdim, Weinstock 2004, Riederer, Lachenmayer & Laux 2004). MAO-A 
metabolizes both serotonin and norepinephrine, two monoamines implicated in depressive 
illness and anxiety disorders (Youdim, Edmondson & Tipton 2006b, ZISOOK, BRAFF & CLICK 
1985). The antidepressive effect of MAO-A inhibitors is associated with blocking the central 
breakdown of these monoamines extending their action. In PD patients, the inhibition of MAO-A 
may be beneficial since a significant proportion of these patients exhibit signs of depression (Di 
Monte et al. 1996a). These inhibitors may also provide a symptomatic benefit by reducing MAO-
A-catalysed oxidation of dopamine (Youdim, Edmondson & Tipton 2006b, Di Monte et al. 1996a) 
and consequently enhancing dopamine level in the human basal ganglia (Kalaria, Mitchell & 
Harik 1988a, Collins et al. 1970a). 
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MAO-B inhibitors are effectively used in treatment of PD (Fernandez, Chen 2007), they act by 
blocking the MAO-B-catalysed metabolism of dopamine and as a result extend the physiological 
action of dopamine in the basal ganglia. They may also boost dopamine levels acquired from 
levodopa, the metabolic precursor of dopamine. As an example, selegiline which inhibits MAO-
B irreversibly can be administered as adjunct to levodopa or as independent therapy, it is 
approved therapeutically for PD worldwide and increases the elevation of dopamine levels after 
levodopa therapy (Di Monte et al. 1996b, Chen, Swope 2005, Finberg et al. 1998). MAO-B 
inhibitors are administered mainly to treat PD, but they may also protect against the 
neurodegenerative processes of this disease. They block the formation of dopanal and H2O2, the 
byproducts of the metabolism of dopamine by MAO-B (Gesi et al. 2001, Lamensdorf et al. 2000). 
These by-products are neurotoxic and may speed up the neurodegenerative process (Kalaria, 
Mitchell & Harik 1988b, Nicotra et al. 2004, Di Monte et al. 1996b, Fowler et al. 1997), therefore 
MAO-B inhibitors may bring about a neuroprotective effect by decreasing MAO-B catalysed 
aldehyde and H2O2 production. 
                                                  
CH
CH3
N
H
     
                                                                  Selegiline                                                           
Anti-apoptotic pathways are activated by compounds containing the propargylamine function and 
this gives the opportunity to have a single compound combining an anti-apoptotic effect with a 
MAO inhibitory effect (Maruyama et al. 2002, Blandini 2005). Selegiline and rasagiline, 
irreversible inhibitors of MAO-B, are examples of such compounds (Edmondson et al. 2003, 
Binda et al. 2005). As an example, rasagiline was shown to provide protection against apoptotic 
cell death in neuroblastoma caused by the pro-apoptotic toxin N-methyl-R-salsolinol. The 
mechanism of action by which these compounds show their anti-apoptotic effect is still not clearly 
defined (Maruyama et al. 2000).  
                                                             
                                                             N-propargylamine                                           
 
N
H
H
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Intracellular enzymes strictly controlling the apoptotic pathway are called caspases. Over a 
dozen caspases have been discovered so far and identified as initiating (e.g. caspases 8, 9 and 
10) and executing caspases (e.g. caspases 3, 6 and 7). Activation of caspase 3 has been 
observed in all kinds of apoptosis (Porter, Jänicke 1999) including neurodegenerative disorders 
(O'Brien, Lee 2004). Among other caspases, caspase 3 is principal in the cleavage of the 
amyloid-precursor protein (APP) alongside its distinct ability to increase neuronal cell death of 
AD affected brains and colocalization of the product of its APP cleavage with amyloid-ß present 
in senile plaques (Albrecht et al. 2007). Polyglutamine causes HD by expanding the N-terminus 
of protein huntingtin, which is a caspase substrate (Chu et al. 2009). To execute the programmed 
type I cell death (apoptosis) caspases 3 is crucial (Limpachayaporn et al. 2013a).  
Nearly all known caspase inhibitors have a common structural characteristic which is an 
electrophilic group that can make a reversible or irreversible bond with the active site cysteine of 
the enzyme and making it inactive (Lee et al. 2001). Synthetic peptide inhibitors including Z-
DEVD-fmk and Z-VAD-fmk have been broadly applied to block type I cell death (Lopez-
Hernandez et al. 2003). Due to the moderate caspase selectivities associated with these 
reagents it is difficult to assess the importance of a specific caspase in apoptosis and this often 
makes the analysis of results ambiguous (Cryns, Yuan 1998, Schotte et al. 1999). To overcome 
this problem, more recently the identification of selective, non-peptidic caspase inhibitors has 
been a center of attention (Deckwerth et al. 2001, Han et al. 2002). Numerous research groups 
have reported their attempt toward small molecule selective caspase 3 inhibitors (Lee et al. 2001, 
Abbavaram, Reddyvari 2013), a selective inhibitor of caspase 3 may give the opportunity to 
evaluate the inhibition of apoptosis potentially at the level of an executioner caspase (Porter, 
Jänicke 1999).  
Isatin sulfonamides were discovered by screening methods and introduced as potent, non-
peptide, selective inhibitors of caspases 3 and 7. In contrast to previously studied peptide-based 
caspase inhibitors, the selectivity of isatin sulfonamides for caspases 3 and 7 results primarily 
from interacting with the S2 subsite, they also do not always bind in primary aspartic acid binding 
pocket (S1) of the caspase (Lee et al. 2000a) (Figure 1.1).   
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                                                             1 (R1 = Ph, R2 = Me) 
                                                                           2 (R1 = Me, R2 = H) 
Figure 1.1: Designated interactions of the general structure of isatin sulfonamides with caspase 
3 and 7 enzyme’s sub-pockets (Limpachayaporn et al. 2013a). 
These group of compounds derived from isatin have been shown to reduce tissue damage in an 
isolated rabbit heart model of ischemia injury and also to block apoptosis in murine bone marrow 
neutrophils and human chondrocytes (Lee et al. 2000a, Chapman et al. 2002). This isatin derived 
compounds (represented by compounds A – D, Figure 1.2) have a higher cell permeability, 
metabolic stability and capability to differentiate apoptosis from necrosis. This may make these 
molecules superior compared to peptide-based inhibitors (Lee et al. 2000a).  
N
H
O
O
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Compound A, IC50 = 15 nM (Lee et al. 
2000b) 
Compound B, IC50 = 1.29 nM (Havran et al. 
2009) 
N 
S 
N 
O O O 
O 
R 
2 
R 
1 
O 
cysteine 
163 
binding site 
S 1 - pocket 
S 2 - pocket 
S 3 - pocket 
 
 
 
 
14 
 
CH3
O O
S
N
O
CH3
N
O
O
 
O O
N
O
O
S
N
O
N
Br
 
Compound C, IC50 = 16.9 nM 
(Limpachayaporn et al. 2013a) 
Compound D, IC50 = 3.6 ± 0.5 nM (Chu et 
al. 2007) 
Figure 1.2: The structure of isatin and the isatin derived caspase 3 inhibitors  
1.3 RATIONAL OF THIS STUDY 
So far there has not been any treatment proven which can simultaneously eliminate the signs 
and symptoms of diseases such as AD and PD and also to stop cell death or bring back damaged 
neurons to a state of normality (Joubert et al. 2011, Zhou, Zhong & Silverman 1996, Ramlawi et 
al. 2006). Disease-modifying approaches have turned into an area of focus in research since 
these strategies interrupt the initial pathologic events associated with the onset of the disease; 
hindering the neurotoxic cascade in the case of neurodegenerative diseases is an example of 
these approaches (McLean et al. 1999, Näslund et al. 2000). Neurodegenerative disorders are 
known to be multifactorial in nature, bearing this in mind, it is evident that the pattern of targeting 
a single disease factor might not be an efficacious strategy for treatment of neurodegenerative 
diseases. 
In clinical practice, multiple targeting has proceeded through the polypharmaceutical approach 
by using a combination of therapeutic agents functioning on different etiological targets 
independently. This approach has been proved to be effective in treatment of diseases with 
similar complexity such as hypertension, cancer and HIV (Jellinger 2003b, Smid et al. 2005). It 
has been proposed that treatment for neurodegenerative diseases will be a blend of drugs having 
different mechanisms of action while acting on more than one related neurotherapeutic target 
(Van der Schyf, Cornelis J, Geldenhuys & Youdim 2006). Treatment with combination 
preparations is, however, a challenging and complex field for drug development due to the 
likelihood of drug–drug interactions and further complications met while combining drug entities 
that have potentially various degrees of bioavailability, metabolism, pharmacokinetic profiles and 
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toxicity (Smid et al. 2005). The design of single drug molecules for a particular disease acting on 
multiple specific etiological targets can be worthwhile especially in neurodegenerative diseases. 
Numerous studies have reported the possibility of having a single drug which acts at several 
sites in the neurotoxic cascade (Smid et al. 2005, Morphy, Rankovic 2005). Taking the complex 
nature of neurodegenerative disorders into consideration, multi-target directed ligands may 
present as a better option to treat neurodegenerative diseases than the classic ‘one molecule, 
one target’ approach (Cavalli et al. 2008, Marlatt et al. 2005). 
1.4 AIM OF STUDY 
From the information above, current research focus moved from a ‘one-drug-one-target 
approach’ to that of drug which is able to act at various relevant biological targets. It was decided 
to design and synthesize multifunctional agents which might halt the apoptotic neuronal 
breakdown process and eliminate the signs and symptoms of diseases such as AD and PD. This 
would happen by: (a) Inhibiting the MAO-A and MAO-B enzymes thus allowing increase in 
dopamine levels in the CNS and reducing the levels of the highly oxidative products produced 
by the activity of this enzyme, and (b) inhibiting apoptotic processes to halt neuronal cell death. 
With this in the mind, the propargylamine portion of selegiline, the isatin moiety and a 
fluorophenylamine function was used as pharmacophoric groups to design potent, non-peptide, 
selective inhibitors of caspases-3 with MAO-A and/or MAO-B inhibitory properties. Therefore, 
the aim of this project was: 
 To provide promising strategies in the development of a multifunctional neuroprotective 
therapeutic single agent for the treatment/prevention of neurodegenerative disorders. 
To reach the aim the following was done: 
 Synthesis of drug-like molecules that comprise of features of both selegiline and isatin. 
 In vitro evaluation of caspase-3, MAO-A and MAO-B inhibition by these compounds.  
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Table 1.1: Assigned names and structures of final compounds selected for synthesis.    
Assigned 
number 
                         Structure and the Name of Compounds  
 
 
 
 
         2 
 
                                 
N
H
O
O
S
O
N
O
F
 
N-[(2-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H- indole-5-sulfonamide                                
 
 
         
 
         3 
                                      
N
H
O
O
S
O
N
O
F
 
N-[(3-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide 
       
 
 
 
         4 
                                       
N
H
O
O
S
O
N
O
F
 
N-[(4-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide 
 
 
 
         5 
                                                      
N
O
O
 
1-(Prop-2-yn-1-yl)-1H-indole-2,3-dione 
 
                    
 
 
 
         7 
                                
N
O
O
S
O
N
O
F
 
N-[(4-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-
sulfonamide 
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         8 
                              
N
O
O
S
O
N
O
F
 
N-[(3-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-
sulfonamide 
 
 
 
 
 
          9 
                                   
N
O
O
S
O
N
O
F
 
N-[(2-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-
sulfonamide 
 
  
 
1.5 CONCLUDING REMARKS 
It is expected that the compounds 7, 8 and 9 will have moderate to high caspase-3, MAO-A and 
MAO-B inhibitory activity since the propargylamine portion of selegiline, the isatin moiety and a 
fluorophenylamine function are used as pharmacophoric groups to design and synthesize these 
compounds therefore they may exhibit the biological properties of the components that they are 
composed of.  
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                                   CHAPTER 2 
                          LITERATURE REVIEW 
 
2.1 NEURODEGENERATIVE DISORDERS 
Huntington’s, Alzheimer’s and Parkinson’s disease are progressive neurodegenerative disorders 
that reduce the quality of life of patients who suffer from these conditions and it is growing into a 
serious problem for the world’s ageing population (Rang 2007). A lot of time and effort have been 
put into identifying the markers and causes of these disorders. Neurodegeneration is the process 
in which neurons in the central nervous system (CNS), and the brain in particular, are damaged 
by several mechanisms (Araki et al. 2001). Progressive and irreversible loss of neurons from 
specific regions of the brain characterizes these disorders (Alexi et al. 2000). 
Not a single cause or process alone can lead to neurodegenerative disorders; instead it is the 
result of several factors which most likely include a variety of mechanistic pathways (Dauer, 
Przedborski 2003). It is postulated that genetic, environmental and endogenous factors are 
probably involved in neurodegenerative disorders such as, Alzheimer’s disease (AD) and 
Parkinson’s disease (PD) and a number of general pathways have been discovered that may be 
among the factors which are involved in different pathogenic cascades. These include 
excitotoxicity, oxidative stress and free radical formation, protein misfolding and aggregation, 
phosphorylation impairment, metal dyshomeostasis and mitochondrial dysfunction. Some of 
these seem to happen simultaneously, resulting in the death of essential neuronal cells (Jellinger 
2003a). 
 
2.2 HUNTINGTON’S DISEASE  
Huntington’s disease (HD) is an inherited autosomal dominant disorder which reveals itself in 
adulthood with symptoms such as clumsiness, temperament and personality changes (Kremer et 
al. 1994) leading to progressive brain degeneration and consequently sharp mental deterioration 
and death (Voisine et al. 2007). HD is the most common disorder among a group of so-called 
trinucleotide repeat neurodegenerative diseases which is characterized by the expansion of the 
number of repeats of the CAG sequence in specific genes and subsequently the number, 40 or 
more, of consecutive glutamine residues at the N-terminal of the expressed protein. (Voisine et 
al. 2007). The protein coded by the HD gene, huntingtin, which normally contains a chain of less 
than 30 glutamine residues, is a soluble cytosolic protein with unknown function found in all cells. 
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When the mutant protein contains 40 or more repeats, HD starts to develop. The expanded 
polyglutamine changes protein folding resulting in the generation of aggregates in neurons which 
appear to be essential for the neurodegenerative process (Goldberg et al. 1996, Bano et al. 2011). 
There is no cure for HD and the treatment is only supportive. Dopamine receptor antagonists, 
such as chlorpromazine, can reduce the involuntary movements and ease the motor symptoms 
(Figure 2.1). Tetrabenazine, an inhibitor of the vesicular monoamine transporter, decreases 
dopamine storage and is used to treat HD symptomatically. The GABA agonist baclofen is also 
another option for the symptomatic treatment of HD. These drugs are not effective against 
dementia and do not delay the progress of the disease. (Rang et al. 2014). 
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Figure 2.1: The structures of symptomatic therapeutic options for HD.  
2.3 ALZHEIMER’S DISEASE  
Degeneration of cognitive ability due to ageing is a normal process whose rate and extent 
fluctuates from one person to another. Alzheimer’s disease (AD) was originally described as 
presenile dementia, but now it seems that the same pathology is involved in the dementia 
regardless of the age of onset. AD is a progressive, degenerative disease of the brain and its 
presence becomes more prevalent with age, it refers to dementia that does not have a previous 
cause, such as brain trauma, stroke or alcohol abuse. Until recently dementia caused by aging 
was thought to be the result of the constant loss of neurons that normally continues throughout 
life and this process is probably hastened by a failure in blood supply connected to 
atherosclerosis. However, studies have shown that certain genetic and molecular mechanisms 
underlie AD (Selkoe 1997, Bossy-Wetzel, Schwarzenbacher & Lipton 2004, Yamada, Nabeshima 
2000). AD is accompanied by localized loss of neurons and shrinkage of brain, mainly in the 
hippocampus and basal forebrain. The loss of cholinergic neurons in the frontal cortex and 
hippocampus is a characteristic hallmark of the disease and is believed to underline the cognitive 
inability and loss of short-term memory that takes place in AD. Decoding the mechanism of 
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neurodegeneration in AD has yet to lead to therapies able to delay the degenerative process. 
Presently, the N-methyl-D-aspartate receptor antagonist, memantine, and cholinesterase 
inhibitors such as donepezil, tacrine and rivastigmine are the only drugs approved for treatment 
of the symptoms accompanying AD (Citron 2004).  
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Figure 2.2: The structures of symptomatic therapeutic options for AD. 
2.4 PARKINSON’S DISEASE  
 PD is the second most common neurodegenerative disorders after AD (de Lau, Breteler 2006) 
and affects nearly 0.3% of the general population. The disorder is clinically characterized by a 
classic triad of signs; including resting tremor, bradykinesia and rigidity (Foye, Lemke & Williams 
2008). It is identified by a specific loss of dopaminergic neurons in the substantia nigra region of 
the brain (Favaloro et al. 2012a) resulting in decreased levels of dopamine in the nerve terminals 
of the striatum in the forebrain (Foye, Lemke & Williams 2008). PD is generally accompanied with 
dementia, depression and autonomic dysfunction. These clinical features of PD arises because 
the degenerative process probably is not only limited to the basal ganglia but also influences other 
parts of the brain. The non-motor symptoms often predominate in the later stages of the disease 
(Rang et al. 2014).  
PD disease is believed to be caused mainly by a combination of genetic and environmental 
factors, but genetic predisposition, predominantly in early-onset PD, has been increasingly seen   
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as the main cause (Schapira, Jenner 2011, Warner, Schapira 2003). Like other 
neurodegenerative disorders, the damage is inflicted by protein misfolding and aggregation, while 
being assisted by other factors namely mitochondrial dysfunction, inflammation and apoptosis, 
oxidative stress and excitotoxicity. (Lotharius, Brundin 2002, Schapira 2008).  
It often takes place with no clear cause underlying it, but it may be due to viral encephalitis, 
cerebral ischaemia or other types of pathological damage. The symptoms can also be attributed 
to therapeutic drug use, the main drugs involved are those which decrease the amount of 
dopamine in the brain (e.g. reserpine) or the ones blocking dopamine receptors (e.g. antipsychotic 
drugs such as chlorpromazine). There are few cases of familial early-onset PD, and several gene 
mutations have been associated, such as those encoding synuclein and parkin. The study of 
these gene mutations has provided some hints into the mechanism which underlies the 
neurodegenerative process (Rang et al. 2014).  
Since current treatments can neither stop the progression of the neurodegenerative process nor 
reverse it, there is no certain cure for PD. However, the symptoms can be brought under control 
with several types of drugs. The drugs used for treatment of PD can either increase the levels of 
DA in the brain or imitate the effects presented by DA (Singh, Pillay & Choonara 2007b). The 
present treatments try to improve the patients’ functional capability for as long as possible. The 
side effects of these agents make limited options available for patients with pre-existing 
cardiovascular complications. Adverse effects such as orthostatic hypotension put the patients at 
the risk of bone fractures (Mukai, Lipsitz 2002). Therefore, newer and more effective agents are 
needed and subject to intense and comprehensive research. Significant research has also 
concentrated on developing enhanced systems for the delivery of existing treatments and agents 
able to halt or reverse the neurodegenerative process. 
2.4.1 Current drugs used for treatment of PD  
2.4.1.1 Levodopa  
This is the main compound for treating PD, used as a precursor of dopamine. When levodopa is 
taken orally it is rapidly decarboxylated and only a small amount of the dose reaches the CNS 
without being changed. Therefore, a large dose is needed for the optimum effect which causes 
nausea and vomiting in patients. In order to tackle this problem levodopa and a peripheral dopa-
decarboxylase inhibitor such as benserazide or carbidopa which cannot penetrate the blood-brain 
barrier are administered in combination (Aminoff 2007). Cardiac arrhythmias is a minor side effect 
for patients who suffer from heart disease. Administration of levodopa has also been attributed to 
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insomnia, depression, agitation and anxiety (Singh, Pillay & Choonara 2007b). Long term 
levodopa therapy is also characterized by several negative motor effects that restrict its use 
including wearing off, the ‘on–off’ phenomena, dose failure, akinesia and dyskinesias (Olanow et 
al. 2004, Jankovic 2005).  
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2.4.1.2 Dopamine receptor agonists 
Dopamine receptor agonists can be classified into two categories; the first class is the ergot 
derivatives such as lisuride, pergolide, bromocriptine, cabergoline and the second class is non-
ergot derivatives such as pramipexole, ropinirole, piribedil or apomorphine. They can be used 
alone to retard the need for levodopa, or may be used with levodopa to raise their efficacy 
(Schapira 2002b, Schapira 2002a, Schapira, Olanow 2003, Schapira 2003). The ergot derivatives 
have the potential to create psychiatric disturbances and cardiovascular disorders that can 
develop into myocardial infarctions and following death. Patients even at lower doses of these 
agents experience dyskinesias, constipation, orthostatic hypotension, confusion and insomnia 
(Katzung 2001a, Wong et al. 2003).  
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2.4.1.3 Amantidine 
It was originally administered as an antiviral for treating influenza, but accidently discovered to 
improve the symptoms of PD. Amantadine is found to act as a non-competitive antagonist at the 
phencyclidine (PCP) site in the NMDA-receptor at therapeutic doses (Danysz et al. 1997). 
Amantadine is also known to increase the release of dopamine from nerve terminals and retard 
its re-uptake (TAKAHASHI et al. 1996, Mizoguchi et al. 1994). Early clinical experiments 
illustrated the antiparkinsonian activity of amantadine either alone or as an adjuvant with levodopa 
(Fahn, Isgreen 1975, Butzer, Silver & Sahs 1975). Unfortunately, all patients do not respond to 
amantadine and tolerance to its effects can occur, although it has been proposed that by 
combining amantadine with levodopa the tolerance is less pronounced (Zeldowicz, Hubermann 
1973). It can potentially have worsening effects on cardiovascular disease and even cause 
seizures in vulnerable patients. Depression, restlessness, confusion and hallucinations are 
considered some of its CNS effects (Singh, Pillay & Choonara 2007a).  
                                                                
NH2
 
                                                                     Amantadine 
 
2.4.1.4 Anticholinergics 
Anticholinergics such as benztropine or trihexyphenidyl are especially effective for controlling 
tremor. In a recent review by the Cochrane database it is mentioned that anticholinergics do not 
potentially have better effects on tremor than on other outcome measures (Katzenschlager et al. 
2002). In addition, these agents do not have much effect on decreasing bradykinesia or akinesia 
(Comella, Tanner 1995). Anticholinergic dosing is also often limited because of their side effects, 
such as drowsiness, agitation, confusion and hallucinations (Katzung 2001b, de Smet et al. 1982).  
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                                                                  Benztropine  
 
2.5 THE ROLE OF APOPTOSIS IN NEURODEGENERATION  
Apoptosis or programmed cell death is a complicated constant mechanism to dispose of surplus, 
potentially dangerous and damaged cells resulting in apoptotic bodies which get cleared without 
activation of the immune system (Hengartner 2000). Apoptosis in physiological cellular processes 
such as control of size and shape of tissue, fetal development, maintenance of the immune 
system, and cell homeostasis, plays a key role. Dysregulation of apoptosis plays a vital role in a 
vast variety of diseases, such as cancer, atherosclerosis, neurodegenerative and developmental 
deficiencies, autoimmune and cardiovascular diseases. (Limpachayaporn et al. 2013b) 
Apoptotic cell death is generally characterized by several subcellular alterations winding up in a 
specific cell death program (Martins, Earnshaw 1997). Three apoptotic stages have been 
identified namely the initiation, effector and degradation stage. In the first stage, the cell 
encounters the death stimulus which may be given by exogenous physical, chemical or biological 
agents or by a shortage of intracellular survival factors. In the next effector phase a number of 
reactions cause cell death triggering. The degradation phase comes after this regulatory step 
which is irreversible and associated with typical morphological and histochemical markers of 
apoptosis such as DNA fragmentation (Kroemer et al. 1995). It has recently been suggested that 
mitochondrial membrane potential is likely to play a vital role in the early events of the apoptotic 
cascade (Kroemer, Zamzami & Susin 1997) 
Regarding PD, the apoptotic process appears most probably as an end-stage process (Anglade 
et al. 1997). For instance, signs of apoptosis, upregulation of the antiapoptotic protein Bcl-2 
(Marshall et al. 1997) and augmented levels of the proapoptotic protein Bax (Hartmann et al. 
2001) have been seen in the substantia nigra of PD patients. In addition, caspase 3 and caspase 
8 may act as effectors of apoptotic cell death in the brain of patients affected with PD (Mogi et al. 
2000, Hartmann et al. 2001). Monoamine oxidase B has also been connected with apoptotic cell 
 
 
 
 
25 
 
death through generating toxic by-products in the aged parkinsonian brain (Kalaria, Mitchell & 
Harik 1988a, Nicotra et al. 2004, Di Monte et al. 1996a, Fowler et al. 1997). 
2.6 MONOAMINE OXIDASES AND ITS ROLE IN APOPTOSIS 
Although the activity of monoamine oxidase (MAO) exists in most mammalian tissues, the two 
isoforms, MAO-A and MAO-B, are presented in a tissue-specific manner. MAO-B is the main form 
found in human liver tissue (Inoue et al. 1999) whereas MAO-A is the major form in human 
placental (Weyler, Salach 1985) and intestinal tissues (Saura et al. 1996). Both isoforms exist in 
the human brain, but they are distributed differently (Westlund et al. 1985, Thorpe et al. 1987). 
MAO-B exists in larger concentrations in both human and subhuman primate brains, and 
demonstrates a higher degree of activity (Fowler et al. 1980, Riachi, Harik 1992). It is particularly 
important to observe that MAO-B is the dominant isoform in the basal ganglia of the human brain 
(Kalaria, Mitchell & Harik 1988a, Collins et al. 1970a) and that the activity and concentration of 
MAO-B increases with age in most brain regions (Kalaria, Mitchell & Harik 1988a, Nicotra et al. 
2004, Fowler et al. 1997). Since MAO-B lies in the glial cells, this heightened activity may be due 
to glial cell proliferation, a process related to increasing age (Westlund et al. 1985, Levitt, Pintar 
& Breakefield 1982, Fowler et al. 2002). On the other hand, MAO-A activity undergoes no changes 
as age increases (Fowler et al. 1980). Neurotransmitter amines are catabolized by MAO-A and –
B therefore they have been targeted for the treatment of neuropsychiatric and neurodegenerative 
diseases (Youdim, Edmondson & Tipton 2006a, Youdim, Weinstock 2004, Riederer, 
Lachenmayer & Laux 2004).  
MAO-A metabolises both serotonin and norepinephrine, two monoamines implicated in 
depressive illness and anxiety disorders (Youdim, Edmondson & Tipton 2006b, ZISOOK, BRAFF 
& CLICK 1985) and the antidepressive effect of MAO-A inhibitors is associated with blocking the 
central breakdown of these monoamines extending their action. Since a significant proportion of 
patients with PD exhibit signs of depression, the inhibition of MAO-A in these patients may be 
beneficial (Di Monte et al. 1996b). Besides offering a potential antidepressant action in PD, MAO-
A inhibitors may also provide a symptomatic benefit by reducing MAO-A-catalysed oxidation of 
dopamine (Youdim, Edmondson & Tipton 2006b, Di Monte et al. 1996b). Although MAO-B is 
present in higher concentrations than MAO-A in the human basal ganglia (Kalaria, Mitchell & 
Harik 1988b, Collins et al. 1970b), MAO-A inhibitors have also been shown to enhance dopamine 
level in this region. For example, clorgyline, a selective irreversible inhibitor of MAO-A, elevates 
dopamine levels in the striatum of primates treated with levodopa to a similar degree than the 
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elevation obtained with selegiline, a selective irreversible inhibitor of MAO-B (Shoulson et al. 
2002a). In order to conserve dopamine in the basal ganglia, mixed MAO-A/B inhibitors may 
therefore be more efficacious than selective inhibitors (Youdim, Bakhle 2006a). 
MAO-B inhibitors are used to treat the symptoms of PD (Fernandez, Chen 2007). The 
effectiveness of MAO-B inhibitors against PD is believed to depend on blocking the MAO-B-
catalysed metabolism of dopamine in the basal ganglia. This preserves exhaustion of dopamine 
stores and extends the physiological action of dopamine. MAO-B inhibitors also may boost 
dopamine levels acquired from levodopa, the metabolic precursor of dopamine. For example it 
has been observed that selegiline, an inhibitor of MAO-B, increases the elevation of dopamine 
levels in the striatum of primates after levodopa therapy (Di Monte et al. 1996a, Chen, Swope 
2005, Finberg et al. 1998). This elevation is characterized by a decline in the oxidative metabolism 
of dopamine (Di Monte et al. 1996a). MAO-B inhibitors are thus suggested as adjuvant treatment 
for levodopa in PD (Fernandez, Chen 2007) and in the early phases of PD, combination therapy 
with MAO-B inhibitors may allow decreasing the doses of levodopa and dopamine agonists 
administered. Moreover, MAO-B inhibitors may also retard the rise of disabilities requiring the 
initiation of levodopa treatment (Shoulson et al. 2002b, Palhagen et al. 1998). MAO-B inhibitors 
modulate central β-phenylethylamine levels and this may also contribute to their beneficial effects 
in PD. Since β-phenylethylamine is both an inhibitor of active dopamine uptake and also a 
releaser of dopamine (Finberg, Lamensdorf & Armoni 2000), blocking its metabolism leads to an 
escalation in striatal extracellular dopamine levels. The central levels of β-phenylethylamine, 
usually only in trace amounts in the CNS, may be enhanced several thousand times by the 
administration of MAO-B inhibitors. 
 
                                           Dopamine                                                                  Dopanal   
Figure 2.3: MAO-B oxidises dopamine and simultaneously reduction of the FAD cofactor of MAO 
takes place. Reoxidation of the FAD through reaction with O2 and ultimately formation of H2O2 
(Joubert et al. 2014a).  
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MAO-B inhibitors are administered clinically mainly to treat PD symptomatically, but they may 
also protect against the neurodegenerative processes of this disease. The mechanism is believed 
to block the formation of dopanal and H2O2, the byproducts of the metabolism of dopamine by 
MAO-B (Gesi et al. 2001, Lamensdorf et al. 2000). The hydrolysis of the iminiumyl intermediate 
produces an aldehyde product in the catalytic cycle of MAO-B, whereas reoxidation of the FAD 
cofactor necessitates the reduction of O2 to H2O2 (Figure 2.3). For each mole of monoamine 
substrate oxidized one mole of these species is produced. Under certain conditions these by-
products are neurotoxic and may speed up the neurodegenerative process. As an example, 
dopanal has been connected with the aggregation of α-synuclein, a process involved in the 
pathological development of PD (Burke et al. 2008). Moreover, the reaction of aldehydic products, 
including dopanal, with N-terminal and lysine ε-amino groups of proteins and exocyclic amino 
groups of nucleosides may occur (Youdim, Bakhle 2006b). Generally aldehydes are quickly 
deactivated by the enzyme aldehyde dehydrogenase (ADH) (Gesi et al. 2001, Marchitti, Deitrich 
& Vasiliou 2007), however in the substantia nigra of patients suffering from PD, the expression of 
ADH maybe decreased. This implies that reduced levels of ADH in the CNS may bring about the 
buildup of aldehydic species resulting from the action of MAO-B (Fowler et al. 1997, Grünblatt et 
al. 2004). H2O2, consequently, may cause oxidative damage by reacting with ferrous ion in the 
Fenton reaction to produce the extremely reactive hydroxyl radical (Youdim, Bakhle 2006b). The 
hydroxyl radical inflicts a lot of damage almost on all types of biomolecules such as proteins, 
lipids, DNA, amino acids and carbohydrates. This reaction may be particularly relevant with this 
knowledge that the iron content of the brain increases with aging. Glutathione peroxidase 
generally inactivates H2O2 in the brain. In the brain affected by PD, the amount of glutathione 
acting as an electron donor for reduction of H2O2 by glutathione peroxidase, may be decreased 
(Riederer et al. 1989). The other mechanism in which H2O2 may aid neurodegeneration is by 
enhancing apoptotic signaling events (Grünblatt et al. 2004, Mallajosyula et al. 2008). Since the 
activity of MAO-B in the CNS rises with age, inhibition of formation of toxic by-products derived 
from the MAO-B catalysis in the aged brain affected by PD is particularly significant (Kalaria, 
Mitchell & Harik 1988a, Nicotra et al. 2004, Di Monte et al. 1996a, Fowler et al. 1997). Therefore, 
MAO-B inhibitors may bring about a neuroprotective effect by stoichiometrically decreasing MAO-
B catalysed aldehyde and H2O2 production. 
Selegiline and rasagiline are approved therapeutically for PD worldwide, they can be administered 
as adjunct to levodopa or as independent therapy. They are both mechanism-based inhibitors 
and inhibit MAO-B irreversibly (Fernandez, Chen 2007). Lazabemide, a reversible MAO-B 
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inhibitor, also appears to delay the requirement for levodopa in untreated patients in the early 
phase of PD (Kieburtz et al. 1996). The benefits presented by lazabemide bore resemblance to 
those observed after 1 year of selegiline therapy (Palhagen et al. 2006, Kieburtz et al. 1996). 
Phase III trials have demonstrated that safinamide, also a reversible MOA-B inhibitor, improves 
motor scores significantly when administered along with dopamine agonist drugs (Stocchi et al. 
2006).   
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Figure 2.4: The structure of some MAO inhibitors. 
2.7 CASPASES AND THE MODULATION OF APOPTOSIS 
Caspases are a set of intracellular enzymes strictly controlling the apoptotic pathway (cysteinyl 
aspartate-specific proteinases). Over a dozen caspases have been discovered so far and 
identified as initiating (e.g. caspases 8, 9 and 10) and executing caspases (e.g. caspases 3, 6 
and 7). Basically two biological pathways are known for the initiation of apoptosis, either by a 
particular protein which binds to the death receptor (death receptor pathway) or by damaging 
DNA and subsequently mitochondrial induction of the cell death program (mitochondrial pathway, 
Figure 2.5). The apoptotic process is driven by signals from both paths cumulating in the activation 
of executing caspases (Limpachayaporn et al. 2013b). Activation of caspase 3 has been observed 
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in all kinds of apoptosis (Porter, Jänicke 1999) including neurodegenerative apoptotic processes 
involved in disorders such as PD, AD, and HD (O'Brien, Lee 2004). Numerous proteins involved 
in cell maintenance and/or repair are natural substrates of caspase 3 (Nicholson, Thornberry 
1997). Caspase 3 is the main caspase participating in the cleavage of amyloid-precursor protein 
(APP) alongside its distinct increase in neuronal cell death of AD brains and colocalization of the 
product of its APP cleavage with amyloid-ß present in senile plaques (Albrecht et al. 2007). 
Polyglutamine causes HD by expanding the N-terminus of protein huntingtin, which is a caspase 
substrate (Chu et al. 2009). 
 
Figure 2.5: Diagram of the dominant molecular pathways resulting in apoptosis. In the 
extrinsic pathway upon ligand binding to specific receptors the formation of DISC complex and 
activation of caspase 8 take place. Cyt c is released from the mitochondria in the intrinsic pathway 
resulting in the formation of the apoptosome and consequently caspase 9 activation. The 
activation of downstream caspases such as caspase 3 by caspase 8 and 9 causes cell death 
(Favaloro et al. 2012b). 
To execute the programmed type I cell death (apoptosis) caspases 3 and 7 are crucial 
(Limpachayaporn et al. 2013a). A significant structural characteristic of nearly all known caspase 
inhibitors is an electrophilic group that can make a reversible or irreversible bond with the active 
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site cysteine making the enzyme inactive (Lee et al. 2001). Synthetic peptide inhibitors including 
Z-DEVD-fmk and Z-VAD-fmk have been broadly applied to block type I cell death. (Lopez-
Hernandez et al. 2003).  
 
O
NH
O
O
NH
O
O CH3
NH
O
O
O
CH3
CH3
CH3
NH O
F
O
O
O
CH3  
O
O
NH
NH
O
CH3
NH O
F
O
OCH3
O
CH3
CH3
 
                                Z-DEVD-fmk, IC50 = 18 µM                               Z-VAD-fmk, IC50 = 40 µM 
 
The involvement of caspases in the process of cell death is more regularly characterized in vitro 
by measuring the activity of the enzyme and evaluation of the inhibitors’ effects in tissue extracts 
and cell lysates. Cell-based studies have been done by using irreversible peptide inhibitors, 
peptide inhibitors having limited cell permeability and pro-drug peptide inhibitors. To assess the 
importance of a specific caspase in apoptosis is difficult, due to the moderate caspase selectivities 
associated with these reagents and this often makes the analysis of results ambiguous (Cryns, 
Yuan 1998, Schotte et al. 1999).  
More recently the identification of selective, non-peptidic caspase inhibitors has been a center of 
attention (Deckwerth et al. 2001, Han et al. 2002). Numerous research groups have reported their 
attempt toward small molecule selective caspase 3 inhibitors (Lee et al. 2001, Abbavaram, 
Reddyvari 2013). Having a selective inhibitor of caspase 3 gives the opportunity to evaluate the 
inhibition of apoptosis potentially at the level of an executioner caspase (Porter, Jänicke 1999). 
Figure 2.6: The structures of two peptide-based caspase inhibitors 
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Screening methods were used to discover isatin sulfonamides and these molecules were 
introduced as potent, non-peptide, selective inhibitors of caspases 3 and 7 (Figure 7 and 8).  
An x-ray co-crystal structure was solved to 2.8 Å resolution to identify the molecular interaction of 
the complex between recombinant human caspase 3 and an isatin sulfonamide inhibitor (Figure 
2.7). In contrast to previously studied peptide-based caspase inhibitors, the selectivity of isatin 
sulfonamides for caspases 3 and 7 results primarily from interacting with the S2 subsite, they also 
do not bind in primary aspartic acid binding pocket (S1) of the caspase. The cysteine of enzyme 
covalently binds at the 3-carbonyl group of isatin leading to formation of a tetrahedral 
thiohemiacetal intermediate (Lee et al. 2000a). 
                                               
                                    1(R1 = Ph, R2 = Me) 
                                    2(R1 = Me, R2 = H) 
 
Figure 2.7: Designated interactions of general structure of isatin sulfonamides with caspase 3 
and 7 enzyme’s sub-pockets (Limpachayaporn et al. 2013a).  
These isatin derived compounds have been shown to reduce tissue damage in an isolated rabbit 
heart model of ischemia injury and also to block apoptosis in murine bone marrow neutrophils and 
human chondrocytes (Lee et al. 2000a, Chapman et al. 2002). Knowing that caspase 3 is 
specifically involved in apoptosis, this group of compounds (represented by compounds A – D, 
Figure 2.8) presenting with higher cell permeability, metabolic stability and their capability to 
differentiate apoptosis from necrosis may make them superior compared to peptide-based 
inhibitors (Lee et al. 2000a). 
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Compound A, IC50 = 15 nM (Lee et al. 2000b) Compound B, IC50 = 1.29 nM (Havran et al. 
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Compound C, IC50 = 16.9 nM 
(Limpachayaporn et al. 2013a) 
Compound D, IC50 = 3.6 ± 0.5 nM (Chu et al. 
2007) 
Figure 2.8: The structure of isatin and the isatin derived caspase 3 inhibitors.  
2.8 ANTI-APOPTOTIC ACTIVITY AND THE PROPARGYLAMINE MOIETY 
Anti-apoptotic pathways are activated by compounds containing the propargylamine function and 
this gives the opportunity to have a single compound combining an anti-apoptotic effect with a 
MAO inhibitory effect (Maruyama et al. 2002, Blandini 2005), selegiline and rasagiline are 
examples of such compounds (see section 2.6). The mechanism-based inhibition demonstrated 
by these compounds is derived from their propargylamine moiety and, after being oxidized by 
MAO, this moiety binds covalently to the FAD cofactor of MAO-B to produce a flavocyanine adduct 
(Edmondson et al. 2003, Binda et al. 2005). The propargylamine moiety is also believed to be 
responsible for the anti-apoptotic effects of this group of compounds. The mechanism of action 
by which these compounds show their anti-apoptotic effect is still not clearly defined.  
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As an example, rasagiline was shown to provide protection against apoptotic cell death in 
neuroblastoma caused by the pro-apoptotic toxin N-methyl-R-salsolinol (Maruyama et al. 2000). 
It is thought that rasagiline exerts this effect, while downregulating pro-apoptotic proteins such as 
Bax and Bad, by inducing the expression anti-apoptotic proteins such as Bcl-2 and Bcl-xL 
(Blandini 2005). This results in the stability of the mitochondrial permeability transition pore, 
consequent reduction in inflammation of the mitochondria, also the decline in mitochondrial 
membrane potential as well as the released cytochrome c (Lemasters et al. 1998).  
The mechanism of anti-apoptotic activity of propargylamines includes several stages of the 
apoptotic pathway and also involves the reduction in caspase 3 activation and polymerase-1 and 
the inhibition of the nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase 
(Blandini 2005, Maruyama et al. 2000, Bar‐Am et al. 2004, Youdim, Weinstock 2001). 
Propargylamines such as rasagiline might perform their neuroprotective activities through the 
activation of pathways of protein kinase C (PKC)-dependent and mitogen-activated protein kinase 
as well as by inducing glial-derived neurotrophic factor and the expression of brain-derived 
neurotrophic factor ((Youdim, Edmondson & Tipton 2006c, Mandel et al. 2005). It is necessary to 
bear in mind that propargylamine containing compounds do not exert their anti-apoptotic effects 
by inhibition of MAO, because even the propargylamines not exhibiting MAO inhibitory activity, 
such as N-propargylamine and the S enantiomer of rasagiline, also show these effects (Binda et 
al. 2005, Youdim et al. 2001). Therefore, the anti-apoptotic properties of this group of compounds 
appear to be an intrinsic characteristic of the propargylamine moiety (Joubert et al. 2014b).  
2.9 MULTI-TARGET-DIRECTED LIGANDS 
So far there has not been any treatment proven to stop cell death or bring back damaged neurons 
to a state of normality (Joubert et al. 2011). Disease-modifying approaches have turned into an 
area of focus in research since these strategies interrupt the initial pathologic events associated 
with the onset of the disease; hindering the neurotoxic cascade in the case of neurodegenerative 
diseases is an example of these approaches (McLean et al. 1999, Näslund et al. 2000). Bearing 
this in mind, it is evident that the pattern of targeting a single disease factor might not be an 
efficacious strategy for treatment of neurodegenerative diseases. 
So far in clinical practice, multiple targeting has proceeded through the polypharmaceutical 
approach by using a combination of therapeutic agents functioning on different etiological targets 
independently. This approach has been proved to be effective in treatment of diseases with similar 
complexity such as hypertension, cancer and HIV (Jellinger 2003b, Smid et al. 2005). It has been 
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proposed that treatment for neurodegenerative diseases will be a blend of drugs having different 
mechanisms of action while acting on more than one related neurotherapeutic target (Van der 
Schyf, Geldenhuys & Youdim 2006). Treatment with combination preparations is, however, a 
challenging and complex field for drug development due to the likelihood of drug–drug interactions 
and further complications met while combining drug entities that have potentially various degrees 
of bioavailability, metabolism, pharmacokinetic profiles and toxicity (Smid et al. 2005).  The design 
of single drug molecules for a particular disease acting on multiple specific etiological targets can 
be worthwhile especially in neurodegenerative diseases. Numerous studies have reported the 
possibility of having a single drug which acts at several sites in the neurotoxic cascade (Smid et 
al. 2005, Morphy, Rankovic 2005).  
This strategy is accompanied with advantages including a lower probability of experiencing 
unwanted side effects, the likelihood to ‘design out’ any side-effects and having pharmacokinetic 
considerations simplified (Van der Schyf, Geldenhuys & Youdim 2006). There has been a shift 
from single to multi-target-directed ligands resulting from the fact that a single compound might 
be capable of hitting multiple targets (Van der Schyf, Cornelis J, Geldenhuys & Youdim 2006, 
Cavalli et al. 2008). Taking the complex nature of neurodegenerative disorders into consideration, 
the multi-target directed ligands may present as a better option to treat neurodegenerative 
diseases than the classic ‘one molecule, one target’ approach (Cavalli et al. 2008, Marlatt et al. 
2005).The requirements for structural activity of an agent at a particular target might become very 
rigorous and structural modification to improve activity at another related target repeatedly may 
result in a pharmacological loss of the original activity, therefore this makes the design of 
multifunctional agents a major challenge (Van der Schyf, Geldenhuys & Youdim 2006, Cavalli et 
al. 2008). 
2.10 CONCLUDING REMARKS 
Design and synthesis of multifunctional drugs which would halt the apoptotic neuronal breakdown 
process and eliminate the signs and symptoms of diseases such as AD and PD may be an 
effective therapeutic option. This can happen by: (a) Inhibiting the MAO-A and/or MAO-B enzymes 
thus allowing increase in dopamine levels in the CNS and reducing the levels of the highly 
oxidative products produced by the activity of this enzyme, and (b) inhibiting apoptotic processes 
to halt neuronal cell death. With this in mind, the propargylamine portion of selegiline and isatin 
can be used as pharmacophoric groups to design potent and selective non-peptide inhibitors of 
caspases-3 with MAO-A and/or MAO-B inhibitory properties. The objective of this project is to 
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design drug-like molecules that comprise of features of both selegiline and isatin, and in so doing 
develop a potential multifunctional single agent to treat neurodegenerative disorders. 
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CHAPTER 3  
                      SYNTHETIC PROCEDURES 
 
3.1. STANDARD EXPERIMENTAL PROCEDURE 
3.1.1. Instrumentation 
Nuclear magnetic resonance spectroscopy (NMR): 1H and 13C NMR spectra were determined 
using Bruker Avance III HD spectrometer at a frequency of 400 MHz and 100 MHz, respectively. 
Tetramethylsilane (TMS) was used as internal standard. All chemical shifts are reported in parts 
per million (ppm) relative to the signal from TMS (δ = 0) added to an appropriate deuterated 
solvent. The following abbreviations are used to describe the multiplicity of the respective signals: 
s - singulet, bs - broad singulet, d - doublet, dd - doublet of doublets, t - triplet, q - quartet and m 
- multiplet. Spectra of selected compounds are included in annexure A.  
Infrared spectroscopy (IR): The IR spectra were recorded on a Perkin Elmer Spectrum 400 
spectrometer, fitted with a diamond attenuated total reflectance (ATR) attachment. Relevant 
spectra are included in annexure A.  
Mass spectroscopy (MS): The MS spectra were recorded on a Perkin Elmer Flexar SQ 300 
mass spectrometer by means of direct injection with a syringe pump. Relevant spectra are 
included in annexure A.  
Melting point determination (MP): Melting points were determined using a Stuart SMP-10 
melting point apparatus and capillary tubes. The melting points are uncorrected.  
Microwave reactor: Microwave synthetic procedures were performed utilising a CEM DiscoverTM 
focused closed vessel reactor.  
3.1.2. Chromatographic techniques  
Thin layer chromatography (TLC): TLC was performed on 0.20 mm thick aluminium silica gel 
sheets (Alugram® SIL G/UV254, Kieselgel 60, Macherey-Nagel, Düren, Germany). Visualisation 
was achieved using UV light (254 nm and 366 nm), an ethanol solution of ninhydrin or iodine 
vapours, with mobile phases prepared on a volume-to-volume basis.  Chromatographic 
purifications were performed by flash chromatography using silica gel (pore size 60 Å, 230-
400 mesh particle size, 40-63 µm particle size) purchased from Sigma-Aldrich® as the stationary 
phase and appropriate mobile phases. 
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3.1.3. Materials 
Unless otherwise stated, all reagents were obtained from Sigma Aldrich and were used without 
further purification.  
3.2. SYNTHESIS OF SELECTED MOLECULES  
The general synthesis reaction is shown below in figure 3.1. The preparation of 5-chlorosulfonyl 
isatin was accomplished starting from the commercially available isatin in two steps, that is, 
sulfonation using tetramethylene sulfone and chlorination with POCl3 (Figure 3.1, step 1). 5-
Chlorosulfonyl isatin was added to the aromatic amine with the fluoro-function in either the ortho, 
meta or para position through a nucleophilic substitution reaction. The resultant compounds were 
coupled with propargyl bromide, using a microwave synthesis procedure, in a nucleophilic 
substitution reaction (Figure 3.1, step 2). 
N
H
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O
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o
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Figure 3.1: The general synthesis of the novel isatin compounds. 
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Table 3.1: Assigned names and structures of final compounds selected for synthesis.   
Assigned 
number 
                         Structure and the Name of Compounds  
 
 
 
 
         2 
 
                                 
N
H
O
O
S
O
N
O
F
 
N-[(2-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H- indole-5-sulfonamide                                
 
 
         
 
         3 
                                      
N
H
O
O
S
O
N
O
F
 
N-[(3-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide 
       
 
 
 
         4 
                                         
N
H
O
O
S
O
N
O
F
 
N-[(4-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide 
 
 
 
         5 
                                                      
N
O
O
 
1-(Prop-2-yn-1-yl)-1H-indole-2,3-dione 
 
                    
 
 
 
         7 
                                
N
O
O
S
O
N
O
F
 
N-[(4-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-
sulfonamide 
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         8 
                              
N
O
O
S
O
N
O
F
 
N-[(3-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-
sulfonamide 
 
 
 
 
 
          9 
                                   
N
O
O
S
O
N
O
F
 
N-[(2-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-
sulfonamide 
 
 
3.2.1. Synthetic procedures 
 
3.2.1.1. 2,3-Dioxoindoline-5-sulfonyl chloride (compound 1) 
  
                   
N
H
O
O
O O
S O
O
N
H
S
+
O
O
Cl
Cl
Cl
O P
Cl
O
O
N
H
S
O
O
+ +
 
 
Synthesis: 2,3-Dioxoindoline-5-sulfonyl chloride was synthesised using a modified procedure 
from the literature (Havran et al. 2009, Martinez, Naarmann 1990). A mixture of isatin-5-sulfonic 
acid sodium salt dihydrate (4 g, 14.04 mmol, 1 eq.) was dissolved in tetramethylene sulfone (20 
mL) and phosphorous oxychloride (7.4 mL, 79.2 mmol, 5.6 eq.) was added dropwise. The mixture 
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was heated at 60 °C for 3 h. The reaction was allowed to cool to room temperature and was added 
dropwise to a stirring slurry of crushed ice/CH2Cl2 (200 g/200 g). After the ice had melted, the 
mixture was separated and the organic layer retained, from which the CH2Cl2 removed was by 
evaporation, diluted with ethyl acetate (200 mL), washed with H2O (10 × 80 mL) and evaporated 
to dryness. The crude product was purified by flash column chromatography using hexane: ethyl 
acetate in a ratio of 1:1 as eluent to yield the title compound, 2,3-dioxoindoline-5-sulfonyl chloride 
(1) as a bright yellow solid. The physical properties of compound 1 was similar to that reported in 
the literature (Havran et al. 2009, Martinez, Naarmann 1990). 
 
3.2.1.2. N-[(2-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfon-
amide (Compound 2) 
                                                                                             
                   
N
H
O
O
S
O
Cl
O +
NH
F
R = H, CH3 N
H
O
O
S
O
N
O
F
  
 
Synthesis: A solution of 1-(2-fluorophenyl)-N-methylmethanamine (0.139 g, 1 mmol) and 
diisopropylethylamine (0.172 g, 1.332 mmol) in CHCl3 (0.733 mL) was added dropwise to a stirred 
solution of 2,3-dioxoindoline-5-sulfonyl chloride (250 mg, 1 mmol) in CHCl3/THF (1:1, 12.65 mL) 
at room temperature. The resulting solution was stirred at room temperature for 1 h and the 
solvent was completely removed in vacuo. The crude product was purified by flash column 
chromatography using hexane: ethyl acetate in a ratio of 1:1 as eluent to obtain N-[(2-
fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide as a brown wax.  
Physical data: C16H13FN2O4S; mp: wax; 1H NMR (200 MHz, CD3OD) (Spectrum 1) δH: 7.83 (d, 
1H), 7.43 (t, 1H), 7.34 (dd, 1H), 7.2 (m, 1H), 7.21-7.1 (m, 3H), 4.25 (s, 2H), 2.64 (s, 3H); 13C NMR 
(50 MHz, CD3OD) (Spectrum 2) δC: 162.34, 159.89, 145.52, 136.87, 133.00, 132.22, 130.89, 
130.58, 130.53, 124.23, 124.19, 123.68, 123.19, 112.54, 46.99, 33.81; MS (DI-ESI-MS) m/z 
(Spectrum 3): 349.11 [M+H]+; IR (ATR, cm-1) vmax (Spectrum 4): 3352.00, 2924.27, 1747.87, 
1614.86, 1333.82, 1151.89 cm-1. 
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3.2.1.3. N-[(3-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfon-
amide (Compound 3) 
                                                      
                       
N
H
O
O
S
O
Cl
O +
NH
F
R = H, CH3 N
H
O
O
S
O
N
O
F
                          
  
Synthesis: A solution of 1-(3-fluorophenyl)-N-methylmethanamine (0.280 g, 2 mmol) and 
diisopropylethylamine (0.350 g, 2.664 mmol) in CHCl3 (1.5 mL) was added dropwise to a stirred 
solution of 2,3-dioxoindoline-5-sulfonyl chloride (0.5 g, 2 mmol) in CHCl3/THF (1:1, 25.3 mL) at 
room temperature. The resulting solution was stirred at room temperature for 1 h and the solvent 
was completely removed in vacuo. The crude product was purified by flash column 
chromatography using hexane: ethyl acetate in a ratio of 1:1 as eluent to obtain N-[(3-
fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide as a light yellow 
powder.  
Physical data: C16H13FN2O4S; mp: 153-155 °C; 1H NMR (200 MHz, CD3OD) (Spectrum 5) δH: 
7.83 (s, 1H), 7.35 (2 x dd, 2H), 7.14 (dd, 1H), 7.09-7.06 (m, 2H), 7.04 (t, 1H), 4.17 (s, 2H), 2.61 
(s, 3H); 13C NMR (50 MHz, CD3OD) (Spectrum 6) δC: 164.27, 161.83, 145.53, 139.08, 138.92, 
132.23, 130.16, 130.13, 130.08, 130.05, 129.00, 123.77, 123.66, 110.49, 53.17, 33.70; MS (DI-
ESI-MS) m/z (Spectrum 7): 349.02 [M+H]+;  IR (ATR, cm-1) vmax (Spectrum 8): 3280.90, 2924.97, 
1750.43, 1614.86, 1336.01, 1147.72 cm-1. 
3.2.1.4. N-[(4-Fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfon-
amide (Compound 4) 
                                                   
                 
N
H
O
O
S
O
Cl
O +
NH
F
R = H, CH3 N
H
O
O
S
O
N
O
F
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Synthesis: A solution of 1-(4-fluorophenyl)-N-methylmethanamine (0.280 g, 2 mmol) and 
diisopropylethylamine (0.350 g, 2.664 mmol) in CHCl3 (1.5 mL) was added dropwise to a stirred 
solution of 2,3-dioxoindoline-5-sulfonyl chloride (0.5 g, 2 mmol) in CHCl3/THF (1:1, 25.3 mL) at 
room temperature. The resulting solution was stirred at room temperature for 1 h and the solvent 
was completely removed in vacuo. The crude product was purified by flash column 
chromatography using Hexane: EtOAc in a ratio of 1:1 as eluent to obtain N-[(4-
fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide as a strong yellow 
powder.  
Physical data: C16H13FN2O4S; mp: 150-152 °C; 1H NMR (200 MHz, CD3OD) (Spectrum 9) δH: 
7.82 (s, 1H), 7.35 (dd, 1H), 7.32 (d, 1H), 7.08-7.05 (m, 4H), 4.13 (s, 2H), 2.55 (s, 3H). 13C NMR 
(50 MHz, CD3OD) (Spectrum 10) δC: 175.87, 165.25, 147.00, 138.40, 133.55, 133.52, 132.48, 
132.07, 131.60, 131.52, 130.52, 125.17, 124.67, 111.99, 54.50, 34.98; MS (DI-ESI-MS) m/z 
(Spectrum 11): 349.01 [M+H]+; IR (ATR, cm-1) vmax (Spectrum 12): 3291.61, 2926.54, 1752.12, 
1614.86, 1334.42, 1146.03 cm-1. 
 
3.2.1.5. 1-(Prop-2-yn-1-yl)-1H-indole-2,3-dione (Compound 5) 
 
                      
+
Br
N
H
O
O
N
O
O
                                                                                                              
 
Synthesis: In a microwave compatible glass-vessel, a stirred solution of isatin (186 mg, 1 mmol) 
dissolved in DMF (6 ml) was treated with NaH (60%, 40 mg, 1 mmol) at room temperature. The 
mixture was stirred for 10 minutes and then propargyl bromide (0.215 ml, 2 mmol) was slowly 
added while stirring. Subsequently the vessel was sealed and the mixture was stirred at 95 °C for 
10 minutes using microwave irradiation (maximum power = 150 W). Thereafter the mixture was 
added to 60 ml of water, extracted with 100 ml of ethyl acetate, washed with 60 ml of saturated 
NaCl and then washed with 60 ml water and dried in vacuo. After solvent removal, the crude 
product was purified by column chromatography using hexane: ethyl acetate in a ratio of 1:1 as 
eluent to obtain the 1-(prop-2-yn-1-yl)-1H-indole-2,3-dione as an orange powder.  
Physical data: C11H7NO2; mp: 159-161 °C; 1H NMR (200 MHz, CDCl3) (Spectrum 13) δH: 7.63 
(m, 1H), 7.25 (m, 1 H), 7.17 (t, 1H), 7.12 (d, 1H), 4.55 (s, 2H), 2.30 (s, 1H).  13C NMR (50 MHz, 
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CDCl3) (Spectrum 14) δC: 182.50, 157.13, 149.59, 138.38, 125.46, 124.18, 117.68, 111.05, 75.64, 
73.31, 29.43; MS (DI-ESI-MS) m/z (Spectrum 15): 186.05 [M+H]+; IR (ATR, cm-1) vmax (Spectrum 
16): 3263.86, 2964.14, 1737.80, 1614.86 cm-1.  
 
3.2.1.6. N-[(4-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-di-hydro-1H-
indole-5-sulfonamide (Compound 7) 
N
H
O
O
S
O
N
O
F
+
Br
N
O
O
S
O
N
O
F
 
 
Synthesis: In a microwave compatible glass-vessel, a stirred solution of N-[(4-
fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide (200 mg, 0.57 
mmol) dissolved in DMF (3.42 ml) was treated with NaH (60%, 11.5 mg, 0.29 mmol) at room 
temperature. The mixture was stirred for 10 minutes and then propargyl bromide (11.5 mg, 0.123 
ml) was slowly added while stirring. Subsequently the vessel was sealed and the mixture was 
stirred at 130 °C for 40 minutes using microwave irradiation (maximum power = 150 W). 
Thereafter the mixture was added to 35 ml of water, extracted with 57 ml of ethyl acetate, washed 
with 35 ml of saturated NaCl and dried in vacuo. After solvent removal, the crude product was 
purified by column chromatography using hexane: ethyl acetate in a ratio of 70:30 as eluent to 
obtain N-[(4-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-di-hydro-1H-indole-
5-sulfonamide as a yellow wax.  
Physical data: C19H15FN2O4S; mp: wax; 1H NMR (200 MHz, CDCl3) (Spectrum 17) δH: 8.37 (s, 
1H), 7.68 (d, 1H), 7.28 (d, 2H), 7.03 (d, 2H), 6.75 (d, 1H), 4.91 (s, 2H), 4.10 (s, 2H), 2.58 (s, 3H), 
2.52 (s, 1H). 13C NMR (50 MHz, CDCl3) (Spectrum 18) δC: 166.29, 161.25, 153.52, 132.95, 
132.29, 131.53, 131.50, 130.13, 124.10, 116.88, 115.67, 115.45, 109.12, 76.71, 75.30, 53.46, 
34.36, 29.70; MS (DI-ESI-MS) m/z (Spectrum 19): 378.20 [M+H]+; IR (ATR, cm-1) vmax (Spectrum 
20): 3289.30, 2921.50, 1695.22, 1621.10, 1334.17, 1152.49 cm-1. 
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3.2.1.7. N-[(3-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-di-hydro-1H-
indole-5-sulfonamide (Compound 8) 
N
H
O
O
S
O
N
O
F
+
Br
N
O
O
S
O
N
O
F
 
 
Synthesis: In a microwave compatible glass-vessel, a stirred solution of N-[(3-
fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-sulfonamide 
(200 mg, 0.57 mmol) dissolved in DMF (3.42 ml) was treated with NaH (60%, 11.5 mg, 0.29 mmol) 
at room temperature. The mixture was stirred for 10 minutes and then propargyl bromide (11.5 
mg, 0.123 ml) was slowly added while stirring. Subsequently the vessel was sealed and the 
mixture was stirred at 130 °C for 40 minutes using microwave irradiation (maximum power = 150 
W). Thereafter the mixture was added to 35 ml of water, extracted with 57 ml of ethyl acetate, 
washed with 35 ml of saturated NaCl and dried in vacuo. After solvent removal, the crude product 
was purified by column chromatography using hexane: ethyl acetate in a ratio of 70:30 as eluent 
to obtain N-[(3-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-di-hydro-
1H-indole-5-sulfonamide as a yellow orange powder.  
Physical data: C19H15FN2O4S; mp: 149-153 °C; 1H NMR (200 MHz, CDCl3) (Spectrum 21) δH: 
8.12 (dd, 1H), 8.06 (dd, 1H), 7.32-7.29 (m, 2H), 7.08 (d, 1H), 7.04 (dd, 1H), 7.01 (s, 1H), 4.61 (s, 
2H), 4.20 (s, 2H), 2.68 (s, 3H), 2.39 (s, 1H); 13C NMR (50 MHz, CDCl3) (Spectrum 22) δC: 164.00, 
161.80, 156.55, 152.29, 137.73, 137.37, 134.22, 130.45, 124.44, 123.83, 117.65, 115.32, 115.26, 
111.65, 74.86, 74.25, 53.67, 34.59, 29.87; MS (DI-ESI-MS) m/z (Spectrum 23): 387.15 [M+H]+; 
IR (ATR, cm-1) vmax (Spectrum 24): 3304.55, 2918.37, 1737.30, 1612.86, 1345.08, 1150.80 cm-1.  
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3.2.1.8. N-[(2-fluorophenyl)methyl]-N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-
indole-5-sulfonamide (Compound 9) 
N
H
O
O
S
O
N
O
F
+
Br
N
O
O
S
O
N
O
F
 
 
Synthesis: In a microwave compatible glass-vessel, a stirred solution of N-[(2-
fluorophenyl)methyl]-N-methyl-2,3-dioxo-2,3-dihydro-1H-indole-5-sulfonamide (30 mg, 0.09 
mmol) dissolved in DMF (0.6 ml) was treated with NaH (60%, 2 mg, 0.05 mmol) at room 
temperature. The mixture was stirred for 10 minutes and then propargyl bromide (0.02 ml) was 
slowly added while stirring. Subsequently the vessel was sealed and the mixture was stirred at 
130 °C for 40 minutes using microwave irradiation (maximum power = 150 W). Thereafter the 
mixture was added to 6 ml of water, extracted with 10 ml of ethyl acetate, washed with 6 ml of 
saturated NaCl and dried in vacuo. After solvent removal, the crude product was purified by TLC 
using hexane: ethyl acetate in a ratio of 40:60 as eluent to obtain N-[(2-fluorophenyl)methyl]-
N-methyl-2,3-dioxo-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole-5-sulfonamide as a yellowish 
brown wax.  
Physical data: C19H15FN2O4S; mp: wax; 1H NMR (200 MHz, CDCl3) (Spectrum 25) δH: 8.12-8.09 
(dd, 1H), 8.03 (d, 1H), 7.45 (d, 1H), 7.30-7.25 (m, 2H), 7.16 (t, 1H), 7.02 (m, 1H), 4.60 (s, 2H), 
4.29 (s, 2H), 2.72 (s, 3H), 2.37 (s, 1H); 13C NMR (50 MHz, CDCl3) (Spectrum 26) δC: 162.23, 
159.77, 156.59, 152.23, 137.36, 134.39, 130.79, 129.99, 124.67, 122.21, 117.59, 115.62, 115.40, 
111.59, 74.89, 74.22, 47.24, 34.76, 29.86; MS (DI-ESI-MS) m/z (Spectrum 27): 387.15 [M+H]+; 
IR (ATR, cm-1) vmax (Spectrum 28): 3275.75, 2917.70, 1744.44, 1610.19, 1323.93, 1152.49 cm-1.  
 
3.3 CONCLUSION 
Seven novel compounds were successfully synthesized, the synthesis of all compounds resulted 
in lower yields that could be attributed to the formation of various unidentified impurities. Varying 
success has thus been achieved with the synthesis of these compounds and its purification. 
Solubility and multiple reactions taking place made it difficult to obtain some of the compounds in 
absolutely pure form and optimization of these reactions for further studies are thus essential. 
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                                  CHAPTER 4 
BIOLOGICAL EVALUATION AND RESULTS 
 
The aim of this study was to design and synthesize a series of hybrid molecules and to evaluate 
these compounds for neuroprotective activity. It is hypothesized that these compounds may have 
the ability to inhibit monoamine oxidases (MAO) and caspase 3, as these drug-like molecules 
comprise of features of both selegiline and isatin which inhibit these two enzymes respectively.  
 
4. IC50 DETERMINATION FOR THE INHIBITION OF HUMAN MAO AND 
CASPASE 3  
 
4.1 IC50 DETERMINATION FOR THE INHIBITION OF HUMAN MAO 
4.1.1 Introduction  
MAO catalyze the oxidative deamination of both endogenous and exogenous molecules, affecting 
the concentration of monoamine neurotransmitters, dietary amines and hormones. This results in 
formation of monoamine aldehydes, which are consequently oxidized to acids by aldehyde 
dehydrogenase or turned into alcohols or glycols by aldehyde reductase. Inhibition of MAO 
increases dopamine levels in the basal ganglia of brain and decreases the formation of oxidative 
by-products (Youdim, Bakhle 2006, Kuhn, Murphy & Youdim 1985, GREEN et al. 1977).  
 
4.1.2 Assay procedure  
This method is based on the fact that certain MAO substrates are oxidized to fluorescent products. 
The substrate used in this study was kynuramine which is oxidized to the fluorescent 4-
hydroxyquinoline. The generation of this product can subsequently be measured with a 
fluorescence spectrophotometer (Zhou, Zhong & Silverman 1996).  This fluorometric method is 
frequently used to determine the activities of recombinant human MAO-A and MAO-B.  It has the 
advantage that it is more sensitive than spectrophotometric methods (Matsumoto et al. 1985) and 
is therefore more suitable to measure activities of recombinant human MAO-A and MAO-B 
(Strydom et al. 2010). Inhibitor potencies are expressed as IC50 values for each inhibitor. 
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Figure 4.1: Conversion of kynuramine to 4-hydroxyquinoline catalyzed by monoamine oxidases 
(Yan et al. 2004).  
4.1.3  Materials and Methods  
4.1.3.1 Chemicals and Reagents  
Isatin (compound 0), potassium dihydrogen orthophosphate (KH2PO4), potassium chloride (KCl), 
dimethyl sulfoxide (DMSO) and recombinant human MAO-A and MAO-B were purchased from 
Sigma Aldrich. The potassium phosphate buffer consisted of 100 mM KH2PO4, the pH was 
adjusted to 7.4 and it was made isotonic with NaCl. Recombinant human MAO-A and MAO-B 
were dissolved in potassium phosphate buffer (0.075 mg/ml) and pre-aliquoted and stored at -70 
ºC before use. The test compounds (including isatin) were ﬁrst dissolved in DMSO and serially 
diluted to the desired concentration range. Clorgyline and selegiline were used as control 
compounds for MAO-A and MAO-B respectively and inhibition percentages were measured at 
four or five different concentrations (0.1 µM, 1 µM, 10 µM, 100 µM and 1000 µM), allowing IC50 
values to be calculated.  
4.1.3.2 Instrumentation    
A Fluorescent Microplate Reader (Biotek Instruments, Inc) and Gen 5® Software were used to 
determine the fluorescence at an excitation wavelength of 310 nm and an emission wavelength 
of 400 nm.  
4.1.3.3 Materials and Method  
All enzymatic reactions were carried out in potassium phosphate buffer to a final volume of 450                                              
µL. DMSO, as co-solvent was added to each reaction. The reactions contained the different test 
inhibitor concentrations. The enzyme reactions were initiated with the addition of MAO-A or MAO-
B and incubated for 10 min at 37 °C. The MAO-A/B substrate kynuramine (45 µM for MAO-A and 
30 µM for MAO-B) was added and further incubated for 20 minutes at 37 °C. Thereafter the 
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reaction was terminated with the addition of 200 µl NaOH (2 N) and the mixture was centrifuged 
by vortex mixer. The fluorescence of the MAO generated 4-hydroxyquinoline in the fractions were 
measured at an excitation wavelength of 310 nm and an emission wavelength of 400 nm. 
4.1.4 Results  
The MAO-A and MAO-B inhibition percentages were calculated and plotted against the logarithm 
of the inhibitor concentrations to obtain a sigmoidal dose-response curve (See. Figures 4.2 -
4.17). Each curve was constructed from four or five different inhibitor concentrations spanning a 
least 3 orders of magnitude. This data was fitted to the one site competition model incorporated 
into GraphPad Prism software and the percentage inhibition at each concentration was 
determined in triplicate and are expressed as mean ± standard deviation. The IC50 value is 
obtained by calculating the concentration of the inhibitor which results in a reduction of 50 % of 
the rate obtained in the absence of inhibitor.  
In order to compare the MAO inhibitory activity of the synthesized compounds they were tested 
in an identical procedure. With regards to MAO-A inhibition, all compounds tested showed 
significant IC50 values. Regarding to MAO-B inhibition, compounds 0, 3, 4, 5, 8 and 9 showed 
significant IC50 values, but compounds 2 and 7 showed low or no inhibition. Compound 1 and 6 
were not evaluated as they were only intermediates and not part of the final series of compounds 
to be evaluated. All the IC50 values obtained from the test compounds are listed in table 4.1 and 
are expressed in µM. Synthesized compounds exhibiting very weak inhibition are expressed in 
the maximum percentage inhibition at the highest possible concentration. The most potent value 
(lowest IC50) for each enzyme is highlighted in grey (Table 4.1).  
4.1.4.1 Dose response curves for MAO-A inhibition studies. 
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Figure 4.2: Inhibition curve of compound 0 on MAO-A activity. 
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Figure 4.3: Inhibition curve of compound 2 on MAO-A activity. 
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Figure 4.4: Inhibition curve of compound 3 on MAO-A activity. 
                                     
-8 -7 -6 -5 -4 -3
0
1 0
2 0
3 0
4 0
5 0
6 0
7 0
8 0
9 0
1 0 0
C o m p o u n d  4
L o g  [M ]
%
 M
A
O
-A
 I
n
h
ib
it
io
n
IC 5 0 =  8 .2 5 9  M
 
Figure 4.5: Inhibition curve of compound 4 on MAO-A activity. 
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Figure 4.6: Inhibition curve of compound 5 on MAO-A activity. 
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Figure 4.7: Inhibition curve of compound 7 on MAO-A activity. 
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Figure 4.8: Inhibition curve of compound 8 on MAO-A activity. 
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Figure 4.9: Inhibition curve of compound 9 on MAO-A activity. 
 
4.1.4.2 Dose response curves for MAO-B inhibition studies. 
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Figure 4.10: Inhibition curve of compound 0 on MAO-B activity. 
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Figure 4.11: Inhibition curve of compound 2 on MAO-B activity. 
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Figure 4.12: Inhibition curve of compound 3 on MAO-B activity. 
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Figure 4.13: Inhibition curve of compound 4 on MAO-B activity. 
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Figure 4.14: Inhibition curve of compound 5 on MAO-B activity. 
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Figure 4.15: Inhibition curve of compound 7 on MAO-B activity. 
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Figure 4.16: Inhibition curve of compound 8 on MAO-B activity. 
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Figure 4.17: Inhibition curve of compound 9 on MAO-B activity. 
4.1.5 Discussion 
Compound 0, isatin, showed some inhibitory activity for MAO-A (IC50 = 10.67 µM). The introduction 
of the aromatic amine with the fluorine in the ortho or meta position (compounds 2 and 3), resulted 
in decreased activity by almost twofold. Compound 4 which has the fluorine in the para position 
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showed increased activity compared to isatin. In compound 5 the propargylamine functional group 
was added to the isatin scaffold, which decreased the MAO-A activity. However the introduction of 
this moiety in compounds 7, 8 and 9 improved the activity when compared to isatin and compounds 
2, 3 and 4 (Figures 4.1-4.9 and Table 4.1).  
Compound 0, displayed some inhibitory activity for MAO-B (IC50 = 12.07 µM). In compound 2, by 
introducing the aromatic amine with the fluorine in the ortho position, the activity was drastically 
reduced (30% inhibition at 100 µM). However, addition of this moiety at the meta or para position 
in compounds 3 and 4 respectively resulted in increased activity. Propargylamine has a significant 
role in MAO-B inhibitory activity of selegiline and rasagiline, but importantly it seems in the 
synthesized compounds that this moiety does not bind to the MAO-B enzyme in a similar manner 
as selegiline and rasagiline. The reduction in MAO-B activity of compounds 5, 7 (20% inhibition at 
10 µM), 8 and 9 confirms this observation. Therefore it can be concluded that compounds 3 and 4 
are the best candidates for MAO-B inhibitory activity (Figures 4.10-4.17 and Table 4.1). 
Compounds 7, 8 and 9 containing the propargylamine functional group are thus selective inhibitors 
of the MAO-A enzyme. These compounds might not find application for neurodegenerative 
disorders but they may be potential candidates as antidepressant agents whereas compounds 3 
and 4 are dually active inhibitors of MAO-A and MAO-B.  Compound 4 is the best dually active 
inhibitor of MAO-A (IC50 = 8.26 µM) and MAO-B (IC50 = 5.96 µM) in this series and a novel lead 
compound for further development. 
 
4.2 IC50 DETERMINATION FOR THE INHIBITION OF HUMAN CASPASE 3 
4.2.1 Introduction  
One of the earliest and most regularly observed attributes that play a role in apoptosis is a family 
of cytosolic proteases called caspases which cleave substrates resulting in apoptotic morphology 
(Keppler-Hafkemeyer, Brinkmann & Pastan 1998, Stennicke, Salvesen 1997). Caspase 3, also 
known as apopain, YAMA, and CPP32, has been identified to be a significant member of this 
caspase family of proteases (Kumar 1999). It is believed that activation of the ICE-family proteases 
and caspase-3 activity are essential for many phenotypes involved in apoptosis in mammalian 
cells. A significant structural characteristic of nearly all known caspase inhibitors is an electrophilic 
group that can make a reversible or irreversible bond with the active site cysteine, making the 
enzyme inactive (Lee et al. 2001). Inhibition of caspases can delay apoptosis, implicating a 
potential drug target against neurodegenerative disorders (Ramlawi et al. 2006, Wei et al. 2006).  
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4.2.2 Assay procedure  
This assay effectively uses fluorometric methods for screening caspase 3 inhibitors by utilizing the 
synthetic peptide substrate DEVD-AFC (AFC, 7-amino-4-trifluoromethyl coumarin). The cleavage 
of the synthetic substrate to active caspase 3 releases free AFC, which is quantifiable by 
fluorometry. To screen a compound, it can be added to the reaction directly and the level to which 
caspase 3 activity is inhibited can be determined by comparing the fluorescence intensity in 
samples with and without the test inhibitors (Ramlawi et al. 2006, Wei et al. 2006). 
4.2.3 Materials and Methods  
4.2.3.1 Chemicals and Reagents  
The caspase 3 inhibitor drug detection kit (ab102491) including 2X reaction buffer 10 mL, caspase 
substrate Ac-DEVD-7-amino-4-trifluoromethyl coumarin (Ac-DEVD-AFC,1 mM), 0.5 mL 
dithiothreitol (DTT, 1 M), 100 µL active caspase 3 (lyophilized, 100 units), and 10 µL of the caspase 
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(O-Me)fluoromethyl ketone (Z-VAD-FMK, 2 mM) was 
purchased from Abcam. The reaction buffer was prepared immediately before use and enough 2X 
reaction buffer was aliquoted for the number of assays to be performed. 10 µl DTT stock solution 
was added to 1 ml of 2X reaction buffer, to reach a 10 mM final concentration. To prepare the active 
caspase 3, 100 units of active caspase 3 was reconstituted in 550 µl 2X reaction buffer then 
aliquoted and immediately stored at -80°C. The test compounds, including purchased isatin 
(compound 0), were ﬁrst dissolved in dimethyl sulfoxide (DMSO) and serially diluted to the desired 
concentration range. Z-VAD-FMK was used as the control compound and inhibition percentages 
of the test compounds were measured at four different concentrations (1 µM, 10 µM, 100 µM and 
1000 µM) in duplicate, allowing IC50 values to be calculated.  
4.2.3.2 Instrumentation  
A Fluorescent Microplate Reader (Biotek Instruments, Inc) and Gen 5® Software were used to 
determine the fluorescence at an excitation wavelength of 400 nm and an emission wavelength 
of 505 nm.  
4.2.3.3 Assay procedure  
The test samples were prepared in DMSO up to a final volume of 50 µl per well, 5 µl of active 
caspase 3 was added and then mixed. A negative and positive inhibition control was prepared by 
adding 1 µl of DMSO and the caspase 3 inhibitor (Z-VAD-FMK) respectively instead of the test 
inhibitor. A 50 µM master mix for each assay containing 45 µl reaction buffer and 5 µl DEVD-AFC 
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substrate was prepared and mixed. The reaction was started by addition of 50 µl of the master mix 
to each well and it was incubated at 37 °C for 1 hour. The samples were read in a fluorescence 
plate reader equipped with a 400 nm excitation filter and 505 nm emission filter. Finally the 
fluorescence intensity of the test samples was compared with samples containing no inhibitors to 
determine the inhibition efficiency of the testing inhibitors.  
4.2.4 Results 
The caspase 3 inhibition percentages were calculated and plotted against the logarithm of the 
inhibitor concentrations to obtain a sigmoidal dose-response curve.  Each curve was constructed 
from 4 different inhibitor concentrations spanning a least 3 orders of magnitude. This data was 
fitted to the one site competition model incorporated into GraphPad Prism software and the 
percentage inhibition at each concentration was determined in duplicate are expressed as mean ± 
standard deviation. The IC50 value is obtained by calculating the concentration of the inhibitor which 
results in a reduction of 50 % of the fluorescence obtained in the absence of inhibitor.  
In order to compare the caspase 3 inhibitory activity of the synthesized compounds they were 
tested in an identical procedure. Compounds 3 and 4 showed excellent inhibitory activity, 
compound 9 showed very good inhibitory activity, compounds 2 and 8 showed good inhibitory 
activity and compounds 0, 5 and 7 showed low or no inhibition. All the IC50 values obtained from 
the caspase 3 inhibitors are shown in figures 4.18 – 4.21 and are listed in table 4.1. Synthesized 
compounds exhibiting weak inhibition (compounds 0, 5 and 7) are expressed in the maximum 
percentage inhibition at the highest concentration. The most potent value (lowest IC50) for each 
enzyme is highlighted in grey (Table 4.1). 
4.2.4.1 Dose response curves for caspase 3 inhibition studies. 
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Figure 4.18: Inhibition curve of compound 2 on caspase 3 activity. 
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Figure 4.19: Inhibition curve of compound 3 on caspase 3 activity. 
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Figure 4.20: Inhibition curve of compound 4 on caspase 3 activity. 
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Figure 4.21: Inhibition curve of compound 8 on caspase 3 activity. 
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Figure 4.22: Inhibition curve of compound 9 on caspase 3 activity. 
4.2.5 Discussion  
Compound 0, isatin, did not display good caspase 3 inhibitory activity (24.5% inhibition at 100 µM). 
As it was mentioned, one of the main reasons of the isatin sulfonamides’ selectivity for caspases 3 
was derived by interacting primarily with the S2 subsite, in other words their sulfonamide moiety is 
responsible for binding to S2 pocket and in compound 0 this moiety does not exist, which may be 
the reason why it does not have caspase 3 inhibitory activity.  
Compounds 2, 3 and 4 has the sulfonamide function conjugated to an aromatic amine with a 
fluorine-moiety substituted at their ortho, meta and para positions respectively. This improved their 
inhibitory activity giving compounds 3 (IC
50 
= 25.08 µM) and 4 (IC
50 
= 29.26 µM) potent caspase 3 
inhibitory activity. In compound 5 the propargylamine functional group was introduced to the isatin 
scaffold and this decreased its activity (18% inhibition at 100 µM), putting it in a similar inhibitory 
activity range as isatin. 
Compound 7, 8 and 9 were synthesized by conjugating the propargylamine moiety to compounds 
2, 3 and 4 respectively. This reduced the inhibitory activity of these compounds compared to their 
counterparts 2, 3 and 4. When comparing compound 8 with compound 3 a twofold reduction was 
observed. Compound 9 in comparison with compound 2 had a slight increase in the activity 
although it is not as active as compounds 3 and 4. The activity of compound 7 (26% inhibition at 
100 µM) compared to compound 4 was drastically reduced. Therefore, based on what was 
observed, the introduction of the propargylamine functional group in general decreased the 
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caspase 3 inhibitory activity. This may indicate that the propargylamine moiety does not fit optimally 
into the S1 pocket of caspase 3 resulting in decreased inhibitory activity.  
Table 4.1: Test compounds with their IC50 values (µM) and maximum percentage MAO- and 
Caspase 3 inhibition. 
Compounds IC
50 
for MAO-A IC
50 
for MAO-B IC
50 
for Caspase 3 
No Controls 0.001 (Clorgyline) 0.36 (Selegiline) 40 (Z-VAD-FMK) 
 
0 
N
H
O
O
 
 
11 
 
12.07 
 
24.5% inhibition at 
100 µM 
 
2 
 
N
H
O
O
S
O
N
O
F
 
 
21.63 
 
30% inhibition at 
100 µM 
 
60.92 
 
 
3 
N
H
O
O
S
O
N
O
F
 
 
 
          22.75 
 
 
          8.329 
 
 
             25.08 
4 
N
H
O
O
S
O
N
O
F
 
 
 
          8.259 
 
 
5.963 
 
 
29.26 
 
5 
N
O
O
 
 
30.91 
 
 
35.19 
 
 
18% inhibition at 100 
µM 
 
7 
N
O
O
S
O
N
O
F
 
 
 
4.306 
 
 
20% inhibition at 
10 µM 
 
 
26% inhibition at 
100µM 
 
 
8 
N
O
O
S
O
N
O
F
 
 
 
10.96 
 
 
70.58 
 
 
51.94 
 
 
 
 
60 
 
 
9 
N
O
O
S
O
N
O
F
 
 
 
9.434 
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4.3 CONCLUSION 
Compounds 3 and 4 are new lead compounds to design multifunctional neuroprotective agents 
because they have good inhibitory activity towards MAO-A, MAO-B and also excellent inhibitory 
activity against caspase 3. Compounds 7, 8 and 9 showed good MAO-A selectivity and do not 
exhibit good MAO-B and caspase 3 inhibitory activities. The role of the aromatic amine functional 
group in the synthesized compounds was significant for their multifunctional activity. The 
introduction of the propargylamine moiety only increased the MAO-A inhibitory activity. For future 
studies it can be recommended to test other functional groups for binding activity in the caspase 
primary aspartic acid binding pocket (S1) to consider improvement in the multifunctional activity. 
In the process of apoptosis there are different apoptotic mechanisms involved. Although 
compounds 7, 8 and 9 did not show good caspase 3 activity, they can be tested for general anti-
apoptotic activity because the propargylamine functional group in these compounds might 
function in a completely different manner than what was tested for in this assay.  
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                                                    CHAPTER 5  
                    SUMMARY AND CONCLUSION 
5.1 INTRODUCTION 
Neurodegeneration is the process in which neurons in the central nervous system (CNS), and the 
brain in particular, are damaged by several mechanisms (Araki et al. 2001). Progressive and 
irreversible loss of neurons from specific regions of the brain characterize these disorders (Alexi 
et al. 2000). Huntington’s disease (HD), Alzheimer’s disease (AD) and Parkinson’s disease (PD) 
are progressive neurodegenerative disorders that reduce the quality of life of patients who suffer 
from these conditions and it is growing into a serious problem for the world’s ageing population. 
Not a single cause or process alone can lead to neurodegenerative disorders; instead it is the 
result of several factors which most likely include a variety of mechanistic pathways (Dauer, 
Przedborski 2003). 
Neurotransmitter amines are catabolized by monoamine oxidase A and B (MAO-A and MAO-B), 
therefore they have been targeted for the treatment of neuropsychiatric and neurodegenerative 
diseases (Youdim, Edmondson & Tipton 2006a, Youdim, Weinstock 2004, Riederer, 
Lachenmayer & Laux 2004). MAO-A metabolizes both serotonin and norepinephrine, two 
monoamines implicated in depressive illness and anxiety disorders (Youdim, Edmondson & 
Tipton 2006b, ZISOOK, BRAFF & CLICK 1985) and the antidepressive effect of MAO-A inhibitors 
is associated with blocking the central breakdown of these monoamines extending their action. 
Since a significant proportion of patients with Parkinson’s disease (PD) exhibit signs of 
depression, the inhibition of MAO-A in these patients may be beneficial (Di Monte et al. 1996a). 
Besides offering a potential antidepressant action in PD, MAO-A inhibitors may also provide a 
symptomatic benefit by reducing MAO-A-catalysed oxidation of dopamine (Youdim, Edmondson 
& Tipton 2006b, Di Monte et al. 1996a). The oxidative deamination reaction catalyzed by MAO-B 
is one of the major catabolic pathways of dopamine in the brain. Inhibition of this enzyme leads 
to enhanced dopaminergic neurotransmission and is currently used in the symptomatic treatment 
of PD (Di Monte et al. 1996a). Furthermore, MAO-B inhibitors may also exert neuroprotective 
effects by reducing the concentration of potentially hazardous by-products produced by MAO-B-
catalysed dopamine oxidation (Kalaria, Mitchell & Harik 1988a, Nicotra et al. 2004, Di Monte et 
al. 1996a, Fowler et al. 1997). Apoptosis or programmed cell death occurs in a number of 
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neurodegenerative disorders. It has been proven that inhibition of the executing enzymes, 
caspases-3 and -7, slows down or even prevent apoptosis (Lee et al. 2000b).  
Disease-modifying approaches have turned into an area of focus in research since these 
strategies interrupt the initial pathologic events associated with the onset of the disease; hindering 
the neurotoxic cascade in the case of neurodegenerative diseases is an example of one of these 
approaches (McLean et al. 1999, Näslund et al. 2000). In clinical practice, multiple targeting has 
proceeded through the polypharmaceutical approach by using a combination of therapeutic 
agents functioning on different etiological targets independently. This approach has been proven 
to be effective in treatment of diseases with similar complexity such as hypertension, cancer and 
HIV (Jellinger 2003b, Smid et al. 2005). Bearing this in mind, it is evident that the pattern of 
targeting a single disease factor might not be an efficacious strategy for treatment of 
neurodegenerative diseases.  
So far there has not been any treatment proven which can stop cell death or bring back damaged 
neurons to a state of normality. We therefore decided to synthesise multifunctional drugs which 
may halt the apoptotic neuronal breakdown process and eliminate the signs and symptoms of 
diseases such as AD and PD. This would happen by: (a) Inhibiting the MAO-A and/or MAO-B 
enzymes thus allowing increase in dopamine levels in the CNS and reducing the levels of the 
highly oxidative products produced by the activity of these enzymes, and (b) Inhibiting apoptotic 
processes to halt neuronal cell death. With this in the mind, the propargylamine portion of 
selegiline, the fluorophenyl function of safinamide, and isatin were used as pharmacophoric 
groups and incorporated into one structure in an attempt to design potent, non-peptide, selective 
inhibitors of caspases-3 with MAO-A and/or MAO-B inhibitory properties.  
Synthesis and enzymatic assays on recombinant human MAO-A, MAO-B and caspase 3 
enzymes were performed to determine the potential of the designed compounds as 
multifunctional neuroprotective therapeutic agents for the treatment/prevention of 
neurodegenerative disorders. 
 
5.2 SYNTHESIS AND CHARACTERISATION 
Seven novel compounds were successfully synthesised utilising multistep processes. The 
synthesis of 5-chlorosulfonyl isatin was accomplished starting from the commercially available 
isatin in two steps, which were, sulfonation using tetramethylene sulfone and chlorination with 
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POCl3. Next 5-chlorosulfonyl isatin was conjugated to the fluorophenylamine derivative with the 
fluoro-function at either the ortho, meta or para position through a nucleophilic substitution 
reaction on the chlorosulfonyl position. The resultant compounds were coupled on the N position 
of the isatin function with propargyl bromide, using a microwave synthesis procedure, in a 
nucleophilic substitution reaction.  
The synthesis of all compounds resulted in moderate to low yields that could be attributed to the 
formation of various unidentified impurities. Varying success has thus been achieved with the 
synthesis of these compounds and its purification. Solubility and multiple reactions taking place 
made it difficult to obtain the compounds in absolutely pure form and optimization of these 
reactions for further use are thus essential. Flash column chromatography was mostly used in the 
purification of the compounds. To confirm the chemical structure of the compounds NMR was 
used and the 13C NMR showed characteristic signals including the signals of the two carbonyls 
on isatin which appeared between 160 -190 ppm thus indicating the presence of the isatin moiety. 
The propargyl moiety which was present in compounds 5, 7, 8 and 9 was identified with the signals 
for its CH and CH2 groups which appeared at around 4.10 and 2.50 ppm respectively. The 
fluorophenylamine function in the synthesized compounds which played a significant role in their 
multifunctional activity was identified in the aromatic region between 6.5 ppm and 8.5 ppm for all 
the novel compounds  The  IR spectra was determined and showed the characteristic signals and 
MS confirmed the molecular masses of the compounds.  
 
5.3 BIOLOGICAL EVALUATION 
In the biological evaluation, recombinant human MAO-A, MAO-B and caspase 3 enzymatic 
assays were performed to determine the activity of the novel compounds at an enzymatic level. 
The activity of test compounds was measured against various controls, clorgyline and selegiline 
for inhibition of MAO-A and MAO-B respectively, and Z-VAD-FMK for caspase 3 inhibition. The 
inhibition percentages for these compounds were calculated and plotted against the logarithm of 
the inhibitor concentrations to obtain a sigmoidal dose-response curve and consequently the IC50 
value was obtained by calculating the concentration of the inhibitor which resulted in a 50 % 
inhibition of the enzyme. In order to compare the MAO and caspase 3 inhibitory activity of the 
synthesized compounds they were tested in identical procedures.  
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Table 5.1: Summary of compounds synthesised and tested with their IC50 values (µM) and 
maximum percentage MAO and Caspase 3 inhibition. 
Compounds IC
50 
for MAO-A IC
50 
for MAO-B IC
50 
for Caspase 3 
No Controls 0.001 (Clorgyline) 0.36 (Selegiline) 40 (Z-VAD-FMK) 
 
0 
N
H
O
O
 
 
11 
 
12.07 
 
24.5% inhibition at 
100 µM 
 
2 
 
N
H
O
O
S
O
N
O
F
 
 
21.63 
 
30% inhibition at 
100 µM 
 
60.92 
 
 
3 
N
H
O
O
S
O
N
O
F
 
 
 
          22.75 
 
 
          8.329 
 
 
             25.08 
4 
N
H
O
O
S
O
N
O
F
 
 
 
          8.259 
 
 
5.963 
 
 
29.26 
 
5 
N
O
O
 
 
30.91 
 
 
35.19 
 
 
18% inhibition at 100 
µM 
 
7 
N
O
O
S
O
N
O
F
 
 
 
4.306 
 
 
20% inhibition at 
10 µM 
 
 
26% inhibition at 100 
µM 
 
 
8 
N
O
O
S
O
N
O
F
 
 
 
10.96 
 
 
70.58 
 
 
51.94 
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9 
N
O
O
S
O
N
O
F
 
 
 
9.434 
 
 
128.2 
 
 
44.74 
 
With regards to MAO-A inhibition, all compounds tested showed meaningful IC50 values (IC50 = 4 
– 30 µM). Regarding MAO-B inhibition, compounds 0, 3, 4, 5, 8 and 9 showed significant IC50 
values (IC50 = 5 – 35 µM), with compounds 2 and 7 showing low or no inhibition (IC50 > 100 µM). 
Compound 1 and 6 were not evaluated as they were only intermediates and not part of the final 
series of compounds to be evaluated. With regards to caspase 3 inhibition, compounds 3 and 4 
showed excellent inhibitory activity (IC50 = 25 – 29 µM), compounds 2, 8 and 9 showed good 
inhibitory activity (IC50 = 44 – 60 µM) and compounds 0, 5 and 7 exhibited low or no inhibition (IC50 
> 100 µM).   
5.4 CONCLUSION 
Neurodegenerative diseases are considered to be multifactorial in nature and taking the complex 
nature of these disorders into consideration, multi-target directed ligands may present as a better 
option to treat these disorders than the classic ‘one molecule, one target’ approach. The 
combination of inhibition properties, selective caspases-3 inhibition with MAO-A and MAO-B 
inhibition, makes the novel structures excellent drug candidates for possible treatment/prevention 
of neurodegenerative disorders.   
The synthesized compounds showed inhibition of the MAO-A, MAO-B and caspase 3 enzymes 
in low to high micro molar concentration. Compounds 3 and 4 are new lead compounds to design 
multifunctional neuroprotective agents because they have good inhibitory activity towards MAO-
A, MAO-B and also excellent inhibitory activity against caspase 3. Compounds 7, 8 and 9 showed 
good MAO-A selectivity and do not exhibit good MAO-B and caspase 3 inhibitory activities. The 
role of the fluorophenylamine in the synthesized compounds was significant for their 
multifunctional activity. The introduction of the propargylamine moiety only increased the MAO-A 
inhibitory activity. For future studies it is recommended to test other functional groups for binding 
activity in the caspase primary aspartic acid binding pocket (S1) to consider improvement in the 
multifunctional activity. In the process of apoptosis there are different apoptotic mechanisms 
involved. Although compounds 7, 8 and 9 did not show good caspase 3 activity, they can be 
tested for general anti-apoptotic activity because the propargylamine functional group in these 
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compounds might function in a completely different manner than what was tested for in this assay 
(Zindo, Joubert & Malan 2015).  
These compounds thus have potential as novel multifunctional neuroprotective agents and further 
investigation is necessary to determine their maximum benefit in the treatment of 
neurodegenerative disorders. 
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                                      Appendix           
                                SPECTRAL DATA: 
                      1H-NMR, 13C-NMR, MS and IR 
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